Which procedure fits your knee — and your life?

Two patients with knee cartilage damage can sit in the same waiting room, describe similar pain, and need completely different treatments. The deciding factors are not just the size of the defect — they are age, activity level, how widespread the damage is, and whether the knee is still fit for surgery.

ChondroFiller injection is an ultrasound-guided outpatient procedure. A collagen scaffold is placed directly into the joint under image guidance, with no general anaesthetic and no theatre time. It is suited to patients with broader or more advanced cartilage wear, those who fall outside surgical criteria — including older patients or those with diffuse damage — and anyone for whom a recovery measured in months is not feasible.

OATS surgery is an operative procedure that transfers a healthy osteochondral plug from a low-load area of the knee to a focal defect. It is best matched to younger, active patients — typically under 45–50 — with an isolated defect of roughly 2–4 cm², well-preserved joint alignment, and low-grade osteoarthritis (Kellgren-Lawrence grade 2 or below).

Neither option is universally superior. A 2024 network meta-analysis of 19 randomised trials found no significant outcome difference between cartilage restoration techniques at any follow-up point, reinforcing that patient and defect profiling — not technique ranking — should drive the choice.

Both treatments are self-funded in the UK; neither is routinely available through standard NHS pathways in Lincolnshire. A consultant assessment is the essential first step.

What ChondroFiller injection does inside the knee

The mechanism matters as much as the procedure. ChondroFiller injection uses an acellular, murine-derived Type I collagen hydrogel manufactured by Meidrix Biomedicals GmbH. On contact with the joint environment, it undergoes rapid in situ polymerisation, forming a three-dimensional scaffold within the area of cartilage damage. That scaffold acts as a physical template: the patient's own progenitor cells migrate into the matrix and begin tissue remodelling — a process described as matrix-induced chondrogenesis.

This is not a lubricant or a simple cushioning agent. The collagen architecture actively recruits repair cells rather than temporarily masking joint surface wear. A 2025 ex vivo study using femoral condyle specimens with standardised 4 mm full-thickness defects found a 2.4-fold increase in DNA content within the scaffold by day 14 — preclinical evidence that active cell migration into the collagen matrix does occur, though larger clinical series are needed to confirm long-term tissue quality.

ChondroFiller injection is CE-marked as a Class III medical device, indicated for Grade III and IV cartilage damage. Because it is delivered as a liquid that gels in situ, a single image-guided injection flows to fill the defect while accessing the whole joint cavity — a different proposition from a graft fixed at a precise surgical site. Standard protocols cover defects up to approximately 3 cm², with some clinical experience extending this further.

Critically, there is no firm upper age limit and no defect-size threshold that automatically excludes a patient. That breadth of eligibility is a meaningful differentiator for anyone who would not meet the strict anatomical and age criteria required for OATS surgery.

What OATS surgery involves

Operating theatre, general or regional anaesthesia, and a recovery measured in months — OATS is a surgical commitment from the outset, and understanding the procedure helps patients judge whether they are likely to be candidates before seeking a formal assessment.

The core concept is a transfer rather than a fabrication. A surgeon harvests one or more cylindrical osteochondral plugs — bone topped with healthy, intact hyaline cartilage — from the medial femoral condyle periphery, a region that bears relatively little load during normal gait. Those plugs are press-fitted arthroscopically into the prepared defect site. The result is an immediate structural repair delivering true hyaline cartilage, the tissue type closest in composition and mechanical behaviour to the original joint surface. No other single-stage technique reproduces this as directly.

The borrowing carries a cost. Removing a plug from one part of the knee to fill another creates a donor site — and while donor-site symptoms are generally modest, they are a recognised trade-off that surgeons discuss openly with candidates before listing.

Patient selection is narrow and deliberate. Alongside the age and defect-size parameters outlined earlier, surgeons typically require a BMI at or below 40, the absence of kissing lesions (opposing cartilage damage on both surfaces), no global chondral change across the joint, and no inflammatory arthritis. These are not administrative thresholds — each criterion reflects a biological reason why the graft is unlikely to integrate or survive long-term if they are not met.

Private OATS surgery in the UK costs approximately £14,000 all-inclusive. Recovery follows a structured timeline: six weeks on crutches with protected weight-bearing, normal walking restored by roughly three months, and return to high-impact sport between six and twelve months post-operatively.

What the clinical evidence shows for each

The evidence base for the two procedures differs in maturity, and that difference is worth naming directly rather than burying in qualifications.

ChondroFiller injection

In the knee, IKDC scores improve by approximately 30 points over 12 months in published series, with a randomised multicentre study confirming significant gains at 3, 6, and 12 months and good MRI defect filling throughout. A separate 2025 clinical study applying the collagen scaffold in joint defects demonstrated significantly better cartilage quality at follow-up assessment compared with untreated controls (median Outerbridge score 1.5 versus 3.0, p=0.006; ICRS 1 versus 3, p=0.002), with no increase in complications. Those results are encouraging. What the evidence does not yet offer is long-term follow-up data beyond 12 months from large cohorts — and that gap should weigh in any honest appraisal.

OATS surgery

OATS carries a more mature dataset. A 2026 systematic review and meta-analysis of 524 patients (mean age 38.7, mean defect 3.36 cm²) reported an IKDC improvement of 40.49 and a VAS pain reduction of 4.27 at a mean follow-up of 54.2 months — a substantially longer window than the ChondroFiller injection trials. In a prospective series of 63 consecutive patients, 78.1% achieved the minimally clinically important difference (MCID) for IKDC at two years; that proportion held to 75% at ten years, with 80% maintaining MCID on the KOS-ADLS functional scale. A separate 2024 series tracking 63 patients with a mean lesion size of 2.3 cm² found IKDC improved from 46.4 to 70.4 over ten years, with only two patients requiring conversion to joint replacement.

What this means for comparing the two

Comparing a 12-month ChondroFiller injection dataset against a 54-month OATS dataset is not a fair fight — the follow-up windows are simply not equivalent. The comparison in the opening section noted that a 2024 Bayesian network meta-analysis of 19 RCTs found no significant outcome difference across technique classes; what that finding underscores here is that technique hierarchy matters less than matching the right approach to the right patient profile. No head-to-head randomised trial has yet tested ChondroFiller injection directly against OATS in the knee — a gap that makes individualised clinical assessment, rather than abstract comparison, the practical starting point.

Cost, recovery, and access from Lincolnshire

Practical planning — cost, travel, and realistic timelines — is often what tips a patient from considering a procedure to actually booking an assessment.

Cost

ChondroFiller injection is priced from £3,000 per box at specialist centres such as London Cartilage Clinic on Harley Street. The package covers consultation, ultrasound guidance, the product itself, injection, antibiotic cover, and a six-week follow-up. It is strictly self-funded: neither NHS commissioning nor private medical insurance currently covers it.

Private OATS surgery costs approximately £14,000 all-inclusive — theatre fees, surgeon, consultant anaesthetist, and twelve months of post-operative follow-up. NHS access is theoretically available via a GP referral to United Lincolnshire Hospitals NHS Trust orthopaedic services, though it requires MRI confirmation and must meet strict clinical criteria before listing is considered.

Recovery contrast

The gap in recovery burden is substantial. ChondroFiller injection is a same-day outpatient procedure; patients mobilise the same day and follow a graduated loading plan without the protected weight-bearing phase that OATS demands. OATS recovery — crutches, structured physiotherapy, and a staged return to activity — is set out in the procedure section above and runs to months rather than days.

Getting there from Lincolnshire

Neither procedure is routinely available close to home for most Lincolnshire patients. A 2025 UK survey of 19 centres found OATS was performed in fewer than half of them, with only 29 cases recorded over five years — a figure that reflects meaningful under-provision rather than limited demand. Finding a surgeon with high-volume OATS experience will, for most people in this county, mean travelling to a specialist centre.

ChondroFiller injection is similarly concentrated at a small number of clinics, currently London-weighted. Both routes therefore involve journey planning, but travelling for a specialist procedure is routine; the more important step is a thorough assessment before committing to either pathway.

Lincolnshire Knee is part of the MSK Doctors group and accepts patients without referral. An assessment at the Sleaford or Grantham clinic — including advanced MRI analysis and, where useful, objective gait evaluation — can establish which pathway is appropriate before any travel for treatment is arranged. Book at lincolnshireknee.co.uk.

Getting the right assessment in Lincolnshire

The two procedures sit at different ends of the intervention spectrum, and the assessment question is more straightforward than it might appear.

If imaging confirms a focal, full-thickness defect — typically under 20 mm, contained borders, surrounding cartilage intact, and Kellgren-Lawrence grade 2 or lower — and the patient is under roughly 50 years of age with a healthy BMI, OATS warrants serious discussion. If the defect is larger or more diffuse, if OA has advanced beyond grade 2, or if age and general health place surgical risk at the forefront, ChondroFiller injection moves to the front of the conversation. Neither judgement can be made reliably on symptoms alone — and selecting a pathway based on cost or recovery length before knowing what the MRI shows risks the wrong treatment for the right reason.

A consultant-led assessment — including MRI analysed with onMRI AI-assisted cartilage segmentation and defect grading, alongside clinical examination — provides the structural picture the decision depends on. Clinics at Sleaford NG34, where Open MRI is on site, and Grantham NG31 offer consultation and imaging without a GP referral or NHS-style waiting.

Lincolnshire Knee is part of the MSK Doctors group and accepts patients without referral. Book an assessment at lincolnshireknee.co.uk.

1. [1] Arthroscopic Osteochondral Autograft Transplantation (OAT) in Patients with Focal Osteochondral/Chondral Lesions of the Knee — Mid-Term Clinical Outcome. (2025). https://doi.org/10.5704/MOJ.2507.004 https://doi.org/10.5704/MOJ.2507.004